Fresenius Kabi USA, LLC, is a fully integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products. Our primary focus is the anesthetic/analgesic, anti-infective, critical care and oncology markets.
We offer one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics throughout North America, and manufacture a comprehensive range of dosage formulations.
Through continuous expansion of our broad portfolio of products, in a range of therapeutic categories, Fresenius Kabi USA, LLC provides affordable healthcare to millions of patients with critical and chronic illness in North America.
Headquartered in Lake Zurich, Illinois, Fresenius Kabi USA, LLC has more than 1,800 employees that are united in their commitment to operational and manufacturing excellence in the ultimate effort to provide products that elevate patient care.
Fresenius Kabi USA, LLC, which was acquired by Fresenius Kabi Pharmaceuticals Holding, Inc., on September 10, 2008, is a company of the Fresenius Kabi Group. Fresenius Kabi USA, LLC, is a wholly owned subsidiary of Fresenius Kabi AG, which is a 100% subsidiary of Fresenius.